Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: A comparison between cardiac MRI, invasive measurements and echocardiography

Clinical Research in Cardiology

Volumn 99, Issue 6, 2010, Pages 359-368

  Sohns, Christian ^a   Sossalla, Samuel ^a   Schmitto, Jan D ^a,b   Jacobshagen, Claudius ^a   Raab, Björn W ^a   Obenauer, Silvia ^a   Maier, Lars S ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiac imaging; CMR; HOCM; TASH

Indexed keywords

ALCOHOL;

ADULT; ANGIOCARDIOGRAPHY; AORTA VALVE; ARTICLE; CARDIOLOGIST; CATHETER ABLATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTRASYSTOLE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IMAGE ANALYSIS; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PRESSURE GRADIENT; RADIOLOGIST; SCAR; TRANSCORONARY ABLATION OF SEPTAL HYPERTROPHY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; AGED; CARDIOMYOPATHY, HYPERTROPHIC; COMPARATIVE STUDY; ECHOGRAPHY; HEART VENTRICLE SEPTUM; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

AGED; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; FEASIBILITY STUDIES; FEMALE; HEART SEPTUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77954660269     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-010-0128-8     Document Type: Article

References (52)

1. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED (2003) ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687-1713
2. Loogen F, Kuhn H, Gietzen F, Loesse B, Schulte HD, Bircks W (1983) Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic nonobstructive cardiomyopathy. Eur Heart J 4:145-153
3. Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE (1987) Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 316:780-789
4. Wigle ED, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 92:1680-1692
5. Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336:775-785
6. Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itsoitz SB, Redwood DR (1975) Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 52: 88-102
7. Maron BJ, Epstein SE, Morrow AG (1983) Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. Eur Heart J 4(suppl F):175-185
8. Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Loesse B, Schwartzkopff B (1999) Management of symptomatic hypertrophic obstructive cardiomyopathy: long-term results after surgical therapy. Thorac Cardiovasc Surg 47:213-218
9. Robbins RC, Stinson EB (1996) Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 111:586-594
10. Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE (1987) Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med 316:844-852
11. Kuhn H, Gietzen F, Ch Leuner, Gerenkamp T (1997) Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: studies to develop a new catheterbased concept of treatment. Eur Heart J 18:846-851
12. Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211-214
13. Gietzen FH, ChJ Leuner, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn HJ (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20:1342-1354
14. Kuhn H, Gietzen FH, Scḧfers M, Freick M, Gockel B, Strunk- Müller C, Jachmann E, Schober O (1999) Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. Eur Heart J 20:1808-1817
15. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Ul Sigwart (1997) Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 95:2075-2081
16. Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98:2415-2421 (Pubitemid 28549785)
17. Lakkis NM, Nagueh SF, Kleimann NS, Killip D, He ZX, Verani MS, Roberts R, Spencer WH 3rd (1998) Echocardiographyguided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98:1750-1755
18. Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, Haberl R, Steinbeck G (2001) Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:846-853
19. Mazur W, Nagueh SF, Lakkis NM, Middelton KJ, Killip D, Roberts R, Spencer WH 3rd (2001) Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 103:1492-1496 (Pubitemid 32226254)
20. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH (2001) Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:1701-1706 (Pubitemid 33065457)
21. Wigle ED, Schwartz L, Woo A, Rakowski H (2001) To ablate or operate? That is the question!. J Am Coll Cardiol 38:1707-1710
22. Fananapazir L, McAreavey D (1998) Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol 31:259-264
23. Kuhn H, Gietzen FH, Leuner C, Scḧfers M, Schober O, Strunk- Müller C, Obergassel L, Freick M, Gockel B, Lieder F, Raute- Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89(4):41-54
24. Spirito P, Maron BJ (1999) Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 33:1071-1075
25. Maron BJ (1999) New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence. Eur Heart J 20:1292-1294
26. Braunwald E (2002) Hypertrophic cardiomyopathy: the benefits of a multidisciplinary approach. N Engl J Med 347:1306-1307
27. Kuhn H, Lawrenz LiederF, Leuner C, Strunk-Müller C, Obergassel L, Bartelsmaer M, Stellbrink C (2008) Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol 97:234-243
28. Sahn DJ, De Maria A, Kisslo J, Weymann A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072-1083
29. Gilbert BW, Pollick C, Adelman AG, Wigle ED (1980) Hypertrophic cardiomyopathy: subclassification by M-mode echocardiography. Am J Cardiol 45:861-872
30. Klues HG, Leuner C, Kuhn H (1992) Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: increase in gradient after exercise. J Am Coll Cardiol 19:527-533
31. Seggewiss H, Faber L, Gleichmann U (1999) Percutaneous transluminal septal ablation in hypertrophic obstruction cardiomyopathy. Thorac Cardiovasc Surg 47:94-100
32. Alam M, Dokainish H, Lakkis N (2006) Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interven Cardiol 19:319-327
33. Seggewiss H, Faber L, Ziemssen P (2000) Age related acute results of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy (abstract). J Am Coll Cardiol 35(Suppl A):188A
34. Sathyamurthy I (2006) Transcoronary ablation of septal hypertrophy (TASH). Indian Heart J 58:371-374
35. Watzinger N, Maier R, Reiter U, Reiter G, Fuernau G, Wonisch M, Fruhwald FM, Schumacher M, Zweiker R, Rienmueller R, Klein W (2005) Clinical applications of cardiovascular magnetic resonance. Curr Pharm Des 11:457-475
36. Bernhardt P, Engels T, Knuf B, Strohm O (2006) Cardiac magnetic resonance in outpatients in Germany-indications, complications and protocol suggestions from a high-volume center. Int J Cardiol 28(111):86-91
37. Schroeder J, Peterschroeder A, Vaske B, Butz T, Barth P, Oldenburg O, Bitter T, Burchert W, Horstkotte D, Langer C (2009) Cardiac volumetry in patients with heart failure and reduced ejection fraction: a comparative study correlating multislice computed tomography and magnetic resonance tomography; reasons for intermodal disagreement. Clin Res Cardiol 98:739-747
38. Pilz G, Bernhardt P, Harrer E, Klos M, Höfling B (2008) Cardiac magnetic resonance imaging: an essential diagnostic aid in suspected myocardial re-infarction in a 40 year old woman. Clin Res Cardiol 97:280-283
39. Schwab J, Haack G, Sinss D, B̈r I, Zahn R (2007) Diagnosis of left ventricular myxoma with cardiac magnetic resonance imaging. Clin Res Cardiol 96:189-190
40. Altbach MI, Squire SW, Kudithipudi V, Castellano L, Sorrell VL (2007) Cardiac MRI is complementary to echocardiography in the assessment of cardiac masses. Echocardiography 24:286-300
41. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM (2000) The use of contrastenhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343:1445-1453
42. Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC (2007) Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol 50:1343-1353
43. Baer FM, Thiessen P, Schneider CA, Voth E, Sechtem U, Schichta H (1998) Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularisation. J Am Coll Cardiol 31:1040-1048
44. Wellhofer E, Olariu A, Klein C, Grafe M, Wahl A, Fleck E, Nagel E (2004) Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation 109:2172-2174
45. Gotte MJ, van Rossum AC, Twisk JWR, Kuijer JPA, Marcus JT, Visser CA (2001) Quantification of regional contractile function after infarction: strain analysis superior to wall thickening analysis in discriminating infarct from remote myocardium. J Am Coll Cardiol 37:808-817
46. Plein S, Kozerke S, Suder D, Luescher TF, Greenwood JP, Boesiger P, Schwittler J (2008) High spatial resolution myocardial perfusion cardiac magnetic resonance for the detection of coronary artery disease. Eur Heart J (Epub ahead of print)
47. Merkle N, Wöhrle J, Nusser T, Grebe O, Spiess J, Torzewski J, Hombach V (2009) Diagnostic performance of magnetic resonance first pass perfusion imaging is equally potent in female compared to male patients with coronary artery disease. Clin Res Cardiol, Sep 11 (Epub ahead of print)
48. Jensen CJ, Bleckmann D, Eberle HC, Nassenstein K, Schlosser T, Sabin GV, Naber CK, Bruder O (2009) A simple MR algorithm for estimation of myocardial salvage following acute ST segment elevation myocardial infarction. Clin Res Cardiol 98:651-656
49. Doesch C, Seeger A, Hoevelborn T, Klumpp B, Fenchel M, Kramer U, Schönfisch B, Claussen CD, Gawaz M, Miller S, May AE (2008) Adenosine stress cardiac magnetic resonance imaging for the assessment of ischemic heart disease. Clin Res Cardiol 97:905-912
50. Veselka J, Duchonová R, Procházková S, Pálenícková J, Sorajja P, Tesar D (2005) Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 95:675-678
51. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H (2007) One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol 96:864-873
52. Lawrenz T, Lieder F, Leuner CJ, Obergassel L, Gockel B, Strunk-Mueller C, Kuhn H (2003) What is the correct amount of ethanol in the catheter based treatment for hypertrophic obstructive cardiomyopathy? Eur Heart J 24(Suppl):136